TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today neurology roundup published Oct. 27, 2026, summarized research on head shape and Alzheimer’s pathology, prenatal phosphatidylcholine and child outcomes, and platelet-count genetics that may affect aspirin’s relationship to dementia prevention. The supplied report gives limited details on the head-shape findings and aspirin analysis, so neither establishes a clinical benefit or cause. A randomized trial reported improved IQ test performance through age 4 among children whose mothers took prenatal phosphatidylcholine, but attention problems were not reduced.
A MedPage Today neurology roundup published Oct. 27, 2026, highlighted three research questions tied to brain health: whether head shape is associated with Alzheimer’s disease pathology, whether prenatal phosphatidylcholine may affect children’s development, and whether genetic differences in platelet counts influence aspirin’s possible role in dementia prevention. The report describes findings from separate studies, not evidence that head shape predicts Alzheimer’s disease or that people should start taking aspirin or choline supplements.
The prenatal nutrition finding came from a randomized trial reported in the American Journal of Obstetrics and Gynecology. The roundup says prenatal phosphatidylcholine supplementation was associated with fewer social withdrawal problems and higher IQ test performance in offspring through age 4. It did not reduce attention problems. The source does not provide the number of participants, supplement dose, size of the measured differences, or details about the comparison group, limiting how fully readers can judge the results.
A separate analysis of data from the ASPREE trial, reported in Alzheimer’s & Dementia, suggested that platelet-count polygenic scores may influence how aspirin might prevent dementia. The report says this could mean some subgroups of older adults benefit differently, but it does not say which groups, quantify any effect, or establish that aspirin prevented dementia. The finding is a possible variation in treatment response, not a recommendation to use aspirin.
The roundup also listed a study on head shape and Alzheimer’s pathology, published in Alzheimer’s & Dementia, but supplied no specific result or study design. It is therefore not possible from this report to say what relationship researchers found, whether the work involved people or another method, or how strong the evidence was. The headline question should not be read as proof that head shape causes Alzheimer’s disease or can be used to assess an individual’s risk.
What These Findings Could Mean
Together, the studies address different stages of brain health: prenatal development, aging, and the biological features that might alter a preventive treatment’s effects. The child-outcome trial is relevant to families and clinicians because it reports measured differences in development through age 4. However, a result on IQ testing does not by itself show lasting effects on learning, daily functioning, or later health, and the report does not provide enough information to assess the magnitude or durability of the differences.
The aspirin analysis matters because preventive treatments can have different effects across groups. If platelet-related genetic profiles eventually help identify who benefits, that could inform research and clinical decisions. For now, the supplied account describes a suggestion from trial data, not a validated way to select patients. Aspirin can have risks, including bleeding, so people should not begin or stop it for dementia prevention on the basis of this summary.
The head-shape topic also illustrates why early research needs careful interpretation. An association with a brain marker, if one was found, would not automatically establish a cause, predict future disease, or provide a useful screening test. The roundup offers too little information to draw even a firm conclusion about the reported association.
Products Worth Considering
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Blueair Blue Pure 211i Max Smart Air Purifier for Large Rooms
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
As an affiliate, we earn on qualifying purchases.
Three Separate Lines of Brain Research
The source is a short news roundup by Judy George, MedPage Today’s deputy managing editor, covering studies and developments across neurology and neuroscience. The three topics here were published in different journals and use different kinds of evidence. The prenatal choline item is described as a randomized trial; the aspirin item is an analysis of ASPREE data; and the head-shape item is identified only by its journal and research question.
That distinction matters. A randomized trial can test an intervention under defined conditions, while an analysis of existing trial data can identify patterns that need further testing. A headline or research question alone does not reveal whether a study found a robust association. The roundup also mentions other work, including a U.K. Alzheimer’s platform trial expected to test repurposed drugs, but it does not connect that trial to these three findings.
“Can head shape influence Alzheimer’s disease pathology?”
— MedPage Today roundup, citing the Alzheimer’s & Dementia head-shape study
Study Details Still Missing
The supplied roundup does not include the head-shape study’s results, design, sample size, or limitations. For the choline trial, key details such as dose, participant numbers, effect sizes, and whether outcomes persist beyond age 4 are absent. The report also does not say whether the findings support routine supplementation or which people, if any, might be considered for it.
For aspirin, the analysis’s size, the genetic-score categories, the magnitude of any difference, and the balance of benefits and harms are not stated. It is also unclear whether researchers tested the proposed subgroup effect prospectively or whether it needs independent replication. These gaps mean the findings cannot support individual medical decisions. The roundup does not establish causation between head shape and disease, durable cognitive benefits from choline, or an aspirin regimen that prevents dementia.
What Researchers Need to Test
Further reporting and publication details are needed to assess the head-shape study and the aspirin analysis. Researchers would need to reproduce any proposed aspirin subgroup effect and establish whether genetic scores can reliably guide decisions while accounting for bleeding risk. For prenatal phosphatidylcholine, longer follow-up could show whether differences in test performance and social withdrawal continue as children grow.
Until those details and follow-up results are available, the practical takeaway is limited: these are research findings to investigate, not instructions to change medication or begin supplements. Readers considering aspirin or prenatal supplements should discuss their circumstances with a qualified health professional.
Key Questions
Does head shape show whether someone will develop Alzheimer’s disease?
The supplied report does not provide the study’s findings or methods. It does not establish that head shape predicts Alzheimer’s disease or causes its pathology.
Did prenatal choline improve children’s IQ?
A randomized trial summarized by MedPage Today reported higher IQ test performance through age 4 among offspring whose mothers received prenatal phosphatidylcholine. The summary does not provide effect sizes or show whether the difference lasts beyond that age.
Should older adults take aspirin to prevent dementia?
No recommendation can be drawn from this roundup. The ASPREE analysis suggested genetic differences may affect aspirin’s possible relationship to dementia, but it did not establish who benefits or provide a treatment plan. Aspirin has risks, including bleeding; discuss its use with a clinician.
Did the prenatal supplement reduce every developmental concern?
No. The report says social withdrawal problems decreased and IQ test performance increased through age 4, but attention problems did not decrease.
Source: medpagetoday.com
